Gilead Sciences Inc. (GILD) Stake Maintained by Shelter Ins Retirement Plan
Shelter Ins Retirement Plan continued to hold its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) during the second quarter, Holdings Channel reports. The firm owned 25,800 shares of the biopharmaceutical company’s stock at the end of the second quarter. Shelter Ins Retirement Plan’s holdings in Gilead Sciences were worth $2,152,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. BNP Paribas Arbitrage SA raised its position in Gilead Sciences by 0.4% in the second quarter. BNP Paribas Arbitrage SA now owns 2,170,640 shares of the biopharmaceutical company’s stock worth $181,075,000 after buying an additional 8,430 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in Gilead Sciences by 17.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,739,537 shares of the biopharmaceutical company’s stock worth $159,794,000 after buying an additional 258,807 shares during the last quarter. Geode Capital Management LLC raised its position in Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock worth $1,137,969,000 after buying an additional 161,505 shares during the last quarter. Temasek Holdings Private Ltd raised its position in Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the last quarter. Finally, Omega Advisors Inc. acquired a new position in Gilead Sciences during the first quarter worth $47,491,000. Institutional investors and hedge funds own 77.93% of the company’s stock.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.42% during trading on Friday, hitting $72.75. 7,359,055 shares of the stock were exchanged. Gilead Sciences Inc. has a 12-month low of $72.21 and a 12-month high of $111.11. The stock has a market cap of $96.01 billion, a P/E ratio of 6.38 and a beta of 1.10. The stock has a 50-day moving average of $77.93 and a 200 day moving average of $84.45.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, topping analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The business earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. During the same quarter last year, the company earned $3.15 earnings per share. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. Equities analysts predict that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is presently 16.56%.
A number of equities analysts recently weighed in on the stock. Piper Jaffray Cos. set a $108.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Sunday, August 21st. Jefferies Group reaffirmed a “hold” rating and set a $96.00 target price on shares of Gilead Sciences in a research note on Wednesday, June 29th. RBC Capital Markets reaffirmed an “outperform” rating and set a $105.00 target price (down from $120.00) on shares of Gilead Sciences in a research note on Tuesday, July 26th. Leerink Swann reaffirmed an “outperform” rating and set a $127.00 target price on shares of Gilead Sciences in a research note on Wednesday, June 29th. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Monday, September 26th. Ten equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $104.71.
In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction on Monday, August 1st. The shares were sold at an average price of $80.50, for a total value of $8,050,000.00. Following the completion of the transaction, the insider now owns 4,119,727 shares of the company’s stock, valued at $331,638,023.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kevin E. Lofton sold 3,500 shares of Gilead Sciences stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $81.97, for a total transaction of $286,895.00. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.